FORMATION OF ACTIVE METABOLITES OF PSYCHOTROPIC-DRUGS - AN UPDATED REVIEW OF THEIR SIGNIFICANCE

被引:63
作者
CACCIA, S
GARATTINI, S
机构
[1] Istituto di Ricerche Farmacologiche, ‘Mario Negri’, Milan, 20157
关键词
D O I
10.2165/00003088-199018060-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Most of the currently available psychotropic drugs form 1 or more active metabolites during in vivo biotransformation in humans and/or animals. In some cases these metabolites are rapidly conjugated and excreted, but in others they attain blood and/or brain concentrations within the same range as, or even higher than, those of the parent drug, thus being potential biologically active compounds. The formation of metabolites with their own biological activity in addition to that of the parent compound may result in a complex situation where different chemical species participate in the final effects. These chemical species may have different pharmacokinetic properties of distribution and clearance. They may act by similar mechanisms, by different mechanisms or even antagonistically. The formation of active metabolites may be important not only for the therapeutic outcome but also for explaining the toxicity of particular drugs. The examples given, although limited, provide evidence that studies on drug metabolites are essential for an understanding of the mechanism of action of psychotropic drugs, and for extrapolating pharmacological and toxicological findings from animals to humans. The development of any new psychotropic agent requires knowledge of the pharmacology and toxicology of all active species as well as their pharmacokinetic profile, including the extent to which they reach the central nervous system. © 1990, Adis Press Limited. All rights reserved.
引用
收藏
页码:434 / 459
页数:26
相关论文
共 125 条
[1]   INDIVIDUAL DIFFERENCES IN PHARMACOKINETICS OF MONOMETHYLATED TRICYCLIC ANTIDEPRESSANTS - ROLE OF GENETIC AND ENVIRONMENTAL FACTORS AND CLINICAL IMPORTANCE [J].
ALEXANDERSON, B ;
SJOQVIST, F .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1971, 179 (JUL6) :739-+
[2]   URINARY-EXCRETION OF NORTRIPTYLINE AND 5 OF ITS METABOLITES IN MAN AFTER SINGLE AND MULTIPLE ORAL DOSES [J].
ALEXANDERSON, B ;
BORGA, O .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1973, 5 (03) :174-180
[3]  
AMSTERDAM J, 1980, AM J PSYCHIAT, V137, P653
[4]   EFFECT OF ACTIVE DRUG METABOLITES ON PLASMA LEVEL-RESPONSE CORRELATIONS [J].
ATKINSON, AJ ;
STRONG, JM .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1977, 5 (02) :95-109
[5]   IMPACT OF ACTIVE METABOLITES ON MONITORING PLASMA-CONCENTRATIONS OF THERAPEUTIC DRUGS [J].
ATKINSON, AJ ;
STEC, GP ;
LERTORA, JJL ;
RUO, TI ;
THENOT, JP .
THERAPEUTIC DRUG MONITORING, 1980, 2 (01) :19-27
[6]   ANTIPSYCHOTIC-DRUGS - CLINICAL PHARMACOKINETICS OF POTENTIAL CANDIDATES FOR PLASMA-CONCENTRATION MONITORING [J].
BALANTGORGIA, AE ;
BALANT, L .
CLINICAL PHARMACOKINETICS, 1987, 13 (02) :65-90
[7]  
BALLABIO M, 1981, ARCH INT PHARMACOD T, V253, P192
[8]   RELATIONSHIP BETWEEN MOLECULAR-STRUCTURE AND CYTOCHROME-P450 METABOLIC INTERMEDIATE COMPLEX-FORMATION, STUDIED WITH ORPHENADRINE ANALOGS [J].
BAST, A ;
SAVENIJECHAPEL, EM ;
NOORDHOEK, J .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1984, 73 (07) :953-956
[9]   FLUOXETINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN DEPRESSIVE-ILLNESS [J].
BENFIELD, P ;
HEEL, RC ;
LEWIS, SP .
DRUGS, 1986, 32 (06) :481-508
[10]   FLUVOXAMINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN DEPRESSIVE-ILLNESS [J].
BENFIELD, P ;
WARD, A .
DRUGS, 1986, 32 (04) :313-334